-
Uncategorized2 weeks ago
Sarepta Pushes Past Gene Therapy Debacle as RNA Therapies Show Early Promise
Biomarker data for Sarepta Therapeutics’ RNA programs, licensed from Arrowhead Pharmaceuticals, are “competitive” and “strong,” according to analysts at Jefferies, which projected over $1 billion in...
-
Uncategorized2 weeks agoDDW Highlights: 26 March 2026
The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates the key stories of the previous week to keep...
-
Endpoints News2 weeks ago
Oral peptides biotech Pinnacle Medicines gets $89M from US, China investors
The pill version of Novo Nordisk’s blockbuster Wegovy showed what was possible when drug chemists turned peptides into oral molecules. Now investors have found their next...
-
ScienceDaily – Biotechnology2 weeks ago
What you do in midlife could reveal how long you’ll live
By closely monitoring fish throughout their lives, researchers found that simple behaviors in midlife—like movement and sleep—can predict lifespan. Fish that stayed active and slept mostly...
-
Uncategorized2 weeks agoObesity could be treated without suppressing appetite
Obesity could be treated in other ways than using drugs suppressing appetite, a study reveals. Researchers identified how brown fat cells, which are linked to weight loss, communicate...
-
Fierce Biotech2 weeks ago
Philips AI cath lab copilot nets FDA clearance
Developed with Edwards Lifesciences, DeviceGuide is aimed at the challenging task of transcatheter mitral valve repair.
-
STAT News – Biotech2 weeks agoSTAT+: Allogene’s off-the-shelf CAR-T is nearing an early but pivotal study readout
This is the online version of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. Why do I...
-
AI & Machine Learning in Biotechnology2 weeks ago
Pulmatrix picked for reverse merger with anti-aging biotech weeks after Cullgen deal collapses
Pulmatrix may have been discarded by Cullgen, but the inhaled therapy biotech’s Nasdaq listing has caught the attention of another company.Read More
-
AI & Machine Learning in Biotechnology2 weeks ago
OrbiMed-backed Pinnacle adds $89M series B to power oral peptide pipeline
Oral peptide specialist Pinnacle Medicines has secured an $89 million series B with backing from investors in the U.S. and China, bringing the company’s total fundraising...
-
Uncategorized2 weeks agoWhitepaper: Secure your place in the IND race
A new exclusive whitepaper is now available from Lonza entitled ‘Secure your place in the IND race with a rapid tox approach‘. Early tox material can...
High-Throughput Platform for Fast-Acting Covalent Protein Therapies
Terns rebuffed a higher bid before selling to Merck
